ArticleRespiratory research2025
Spontaneous pneumomediastinum and/or pneumothorax in anti-MDA5 dermatomyositis: a refined staging system.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Clinical phenotype and prognostic determinants of spontaneous pneumomediastinum in anti-MDA5 antibody-positive dermatomyositis.Frontiers in immunology · 2026Article
- Case Report: Lung transplantation for rare anti-MDA5-positive rapidly progressive interstitial lung disease: two cases and a narrative review.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSpontaneous pneumomediastinum and/or pneumothorax (SPM/P) have been Linked to unfavorable outcome in anti-melanoma differentiation-associated gene 5 positive dermatomyositis (MDA5+DM) patients. This study attempted to investigate the prognostic value of SPM/P and identify the predisposing factors of SPM/P in patients with interstitial lung disease (ILD) complicated with MDA5+DM.
methodsThis study was conducted in a large inception cohort of MDA5+DM-ILD (from 2014 to 2023) at Shanghai Renji Hospital. Baseline demographic data, pulmonary function tests, high-resolution CT imaging, laboratory parameters and survival status within 12 months were collected and compared between survivors and deceased patients, as well as between patients with and without SPM/P. Kaplan–Meier curves were plotted and Cox regression models were applied to identify prognostic factors. Furthermore, logistic regression analysis was employed to determine the predictors of SPM/P development.
resultsIn a cohort of 523 MDA5+DM-ILD patients, 92 (17.6%) developed SPM/P. Of those, 63 SPM/P cases occurred within 3 months since ILD onset and had a significantly higher 12-month mortality than those without SPM/P (82.5% versus. 35.4%, p < 0.001). Multivariable Cox regression model identified SPM/P occurred within 3 months as an independent risk factor for survival (HR 1.59, 95% CI 1.09–2.34, P = 0.018). Predisposing factors for SPM/P included severe restrictive ventilation dysfunction, male sex, and CMV viremia.
conclusionsSPM/P occurred within 3 months since ILD onset was identified as a poor prognostic factor in MDA5+DM-ILD. A refined FVC%-based staging system combining SPM/P was proposed for better risk stratification and to gauge clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.